Trailhead Biosystems Raises US$ 6.6 Million in Series A Round

USA-based Therapeutic cell pioneer Trailhead Biosystems raises US$ 6.6M in Series A funding for the development of specialized human cells.

Critical support in closing the Series A financing was provided by the Entrepreneurship & Innovation Clinic at Yale Law School.

About Trailhead Biosystems

Founded in 2015 by Jan Jensen, Trailhead Biosystems has developed a proprietary platform to perform systems-level interrogation of complex biological problems, ranging from the generation of industrially-scalable manufacturing conditions for specialized human cells to combinatorial drug discovery in cancer and anti-viral therapies. It robotically conducts the dimensioned experiments in biology, using machine learning to discover critical process parameters and combinatorial inputs that explain biological responses. Trailhead’s research methods depart radically from the limited explorative power of standard hypothesis-driven research.

“Biology is complex, but conventional science is not. We created Trailhead Biosystems to address key limitations in the scientific process, unlocking a deeper understanding of the biology that will enable us to better control it,” said Jan Jensen, PhD, Chief Executive Officer and founder of Trailhead Biosystems.

The company has converted the traditional discovery process into one centered on systematic engineering to determine critical process parameters for the manufacture of human cells. “Experimental depth matters. Small-sized experiments fail to capture the complexity of biology. But as we increase dimensionality, we break through. The relevant information we need is now available, and we obtain the ability not only to discover conditions to make novel cell types, but we also gain the process understanding needed for their manufacture,” said Jan Jensen.

Trailhead wishes to rapidly develop its capability of creating specialized human cell types at high purity for regenerative medicine and therapeutic purposes at an industrial scale. It is aiming to address the current industry needs for highly specialized cells used in drug discovery and modelling of human diseases.

The company currently develops products that target type I diabetes, Parkinson’s disease, Multiple Sclerosis, Alzheimer’s disease, and blood disorders, among others.

“Trailhead is a key enabling technology developer who works closely with the Advanced Regenerative Manufacturing Institute (ARMI),” said Tom Bollenbach, Chief Technical Officer of Trailhead. ARMI is a U.S. Department of Defence-funded manufacturing innovation institute focused on enabling the scalable, consistent and cost-effective manufacturing of cell therapies and tissue engineered medical products.

Magnus Persson, M.D., PhD, a biotech entrepreneur and Chairman of the Board of Trailhead Biosystems said, “This Series A financing round is a great vote of confidence in our cutting-edge technology and will allow the company to progress its programs to benefit patients. We are excited to realize our future objective of becoming a key provider of therapeutic human cells to the regenerative medicine industry.”

What Investors have to say

“The Entrepreneurship & Innovation Clinic at Yale Law School was founded as a teaching clinic to work with highly innovative ventures in need of sophisticated legal and transactional advice. We were delighted to take on Trailhead Biosystems as a client and to support the company through this financing,” said Sven Riethmueller, Clinical Associate Professor of Law at Yale Law School and the inaugural Director of the Entrepreneurship & Innovation Clinic.

We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Story